Abivax stock
ABVX.PAPARAbivax S.A., HealthcareISIN FR0012333284
35Score 35 out of 100, Weak
Price and trend
44 / 100
Price history
−9.1% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 16% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is 39% below its 52-week high. Largest decline in 11 years: 87% (January 2021 to April 2025).
Chart figures for advanced users
- SMA 50$93.63
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$108.68
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$69.92
- The lowest closing price of the last twelve months.
- Resistance$149.59
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Abivax S.A. belongs to the Biotechnology industry (France) and, with a market value of $8B, is number 48 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 35 out of 100 (Weak): rank 602 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 100% over the last 12 months, Biotechnology median −103.7%.
- More cash than debtCash $587.72M, financial debt $35.56M.Stability 54
Weaknesses
- DilutionShare count up 386% since 2020.Capital allocation 18
- Loss-makingLoss of $372.43M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 83% a year over the last 12 months.Stability 54
The score is held back by capital allocation and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 36 to 35.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%. Last 12 months: net 100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 14 Dec 2026in 31 days
- Last reported
- 21 Sep 2026EPS reported −$1.63 (expected −$0.89)below expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 5.4% since 15 Oct 2026.
- Earnings per share
- −$4.07+2.0%
- Revenue
- $4.69M+9.2%
- Earnings per share
- −$3.85+5.4%
- Revenue
- $82.96M+60.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Abivax
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Protagonist TherapeuticsPTGX $8.77B68
- Asymchem Laboratories (Tianjin)002821.SZ $8.29B64
- RemeGen688331.SS $8.26B44
- ALK-AbellóALK-B.CO $8.18B74
- CytokineticsCYTK $7.82B33
- 10x GenomicsTXG $7.73B43
- Rhythm PharmaceuticalsRYTM $7.62B41
- Axsome TherapeuticsAXSM $7.59B31
ETFs that hold Abivax
Held by 89 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 2.26% | 0.89% | €11.72M |
| iShares EURO STOXX Mid UCITS ETFIQQM | 0.72% | 0.40% | €560.15M |
| iShares MSCI EMU Mid Cap UCITS ETF EURIS3H | 0.47% | 0.49% | €570.32M |
Show 5 more
| iShares STOXX Europe Mid 200 UCITS ETF (DE)EXSD | 0.35% | 0.20% | €634.13M |
| iShares MSCI Europe Mid-Cap Equal Weight UCITS ETFCEMT | 0.34% | 0.25% | €36.34M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 0.32% | 0.46% | €722.41M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.32% | 0.35% | €1.25B |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 0.29% | 0.17% | €362.64M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.